• 1
    Wolach C, Bairey O, Lahav M. Late-onset neutropenia after rituximab treatment: case series and comprehensive review of the literature. Medicine (Baltimore) 2010; 89: 30818.
  • 2
    Rios-Fernandez R, Gutierrez-Salmeron MT, Callejas-Rubio JL, Fernandez-Pugnaire M, Ortego-Centeno N. Late-onset neutropenia following rituximab treatment in patients with autoimmune diseases. Br J Dermatol 2007; 157: 12713.
  • 3
    Marotte H, Paintaud G, Watier H, Miossec P. Rituximab-related late-onset neutropenia in a patient with severe rheumatoid arthritis. Ann Rheum Dis 2008; 67: 8934.
  • 4
    Jones RB, Ferraro AJ, Chaudhry AN, Brogan P, Salama AD, Smith KG, et al. A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody–associated vasculitis. Arthritis Rheum 2009; 60: 215668.
  • 5
    Rhee EP, Laliberte KA, Niles JL. Rituximab as maintenance therapy for anti-neutrophil cytoplasmic antibody-associated vasculitis. Clin J Am Soc Nephrol 2010; 5: 135962.
  • 6
    Cancer Therapy Evaluation Program. Common Toxicity Criteria version 2.0 (CTC). Bethesda (MD): Department of Health and Human Services, National Institutes of Health, National Cancer Institute; 1999.
  • 7
    Leandro MJ, Cambridge G, Ehrenstein MR, Edwards JC. Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum 2006; 54: 61320.
  • 8
    Tesfa D, Gelius T, Sander B, Kimby E, Fadeel B, Palmblad J, et al. Late-onset neutropenia associated with rituximab therapy: evidence for a maturation arrest at the (pro)myelocyte stage of granulopoiesis. Med Oncol 2008; 25: 3749.
  • 9
    Gottenberg JE, Ravaud P, Bardin T, Cacoub P, Cantagrel A, Combe B, et al. Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the AutoImmunity and Rituximab registry. Arthritis Rheum 2010; 62: 262532.
  • 10
    Anolik JH, Campbell D, Felgar RE, Young F, Sanz I, Rosenblatt J, et al. The relationship of FcγRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum 2003; 48: 4559.
  • 11
    Terrier B, Ittah M, Tourneur L, Louache F, Soumelis V, Lavie F, et al. Late-onset neutropenia following rituximab results from a hematopoietic lineage competition due to an excessive BAFF-induced B-cell recovery. Haematologica 2007; 92: e203.